RDNZ actively engages with rare disease issues by responding to calls for submissions.

 

Mar 11, 2024, 11:28 AM
Submission on proposal to fund vaccine for the prevention of shingles in immunocompromised people

Rare Disorders NZ supports the principles behind the proposal to widen the access for recombinant varicella zoster virus vaccine (branded as Shingrix) for prevention of shingles in immunocompromised people. However, we are concerned by the very narrow criteria.

Feb 8, 2024, 10:23 PM
Submission to Pharmac on proposal to decline inactive funding applications

Rare Disorders NZ is pleased to see Pharmac aiming to provide more clarity about which medicines they are actively considering for funding.

Dec 4, 2023, 2:10 PM
Submission to Pharmac on Proposal to fund supplements for phenylketonuria

We are pleased to see that people with phenylketonuria (PKU) are now having their unmet needs recognised, and New Zealand is making steps towards meeting internationally recognised standards of care.

Sep 21, 2023, 12:20 PM
RDNZ submission on draft statement on disclosure of harm following an adverse event

Rare Disorders NZ made a submission calling for misdiagnosis and delayed diagnosis to be recognised as causing harm. 

Aug 17, 2023, 12:25 PM
Submission to Pharmac on proposal to change the access criteria for COVID-19 antiviral treatments

Rare Disorders NZ has been advocating for the widening of access to COVID-19 antiviral treatment for some time and has made a submission to Pharmac on the proposal to change the access criteria.

Jul 9, 2023, 11:04 PM
Submission to Pharmac on Proposal to fund Emicizumab for severe Haemophillia A

Rare Disorders NZ supports the proposal to widen access to emicizumab, brand name Hemlibra, for the treatment of severe Haemophilia A without FVIII inhibitors, subject to eligibility criteria.

Jul 9, 2023, 10:56 PM
Submission to Pharmac on Proposal to fund Ocrelizumab for Primary Progressive Multiple Sclerosis

Rare Disorders NZ supports the changes proposed to the Special Authority Criteria to include access for people with PPMS for Ocrelizumab specifically.

Mar 28, 2023, 11:01 PM
Submission to Pharmac’s review proposal to phase out funding of food thickeners

Rare Disorders NZ proposes that Pharmac does not phase out food thickeners but widen access to include other causes of dysphagia and rare disorders such as Head and Neck cancer.

Mar 20, 2023, 2:38 PM
Submission to Pae Ora Health of Disabled People Strategy

For most rare disorder patients, they experience forms of disability as a result of their condition. Unfortunately, the existing disability support system has proven unable to consistently meet the needs of the rare disorder community in New Zealand.

Mar 20, 2023, 2:25 PM
Submission to the Pae Ora Women’s Health Strategy

Rare disorders affect women, in fact possibly more so than other groups of the population, especially due to women often taking the main carer role.